Phase 1 HIV clinical study

Data has been obtained from our phase 1 HIV clinical study described here:

Study Design: Patients that are successfully treated with highly active anti-retroviral therapy (HAART) with no measurable viral load AND have a cryopreserved infectious plasma sample that was drawn immediately prior to initiation of HAART are administered 4 monthly doses of the Arcelis product.

Current status: This trial is fully enrolled. Immune response data is encouraging in the first 7 patients for which the analysis has been completed. Six of 7 patients developed CD8+ T-cell immune reactivity to several HIV antigens. Importantly, the expanded HIV-specific T cells are CD28+ effector memory cells, known to associated with long-term non-progression. The product was well-tolerated with no serious adverse events reported.

• molecule type
• CD8,
• HIV antigen,
• CD28 receptor

• organism type
• Homo sapiens

• cell type
• effector memory T cell

• bodily part type
• blood plasma

• experimental design type
• in vivo design experiment

• experimental factor type
• Clinical treatment factor

created over 15 years ago (2 March 2009)    last modified over 13 years ago (20 October 2011)   [ RDF ]   [ RelFinder ]